Johnson & Johnson ($JNJ) has partnered with a microbiome startup in its JLABS San Diego incubator to develop treatments for inflammatory skin diseases.

A snapshot survey of biotech chiefs during the second quarter has shown that their confidence to be able to raise funds has doubled since Q1, but they are a…

Bristol-Myers Squibb is adding to an existing partnership with Bavarian Nordic to start a Phase II combo trial of Opdivo with Bavarian’s cancer vaccine CV301…

Preclinical microcap Eleven Biotherapeutics hopes to press the reset button by refocusing on a Roche deal that could continue to offer infusions of cash, or be…

Bristol-Myers Squibb is buying back Asia rights that it outlicensed to Aslan Pharmaceutical after almost 5 years--and some Phase I data.

Eli Lilly will continue its late-stage breast cancer cocktail trial after its CDK4/CDK6 candidate, when used alongside AstraZeneca’s marketed Faslodex (…

Partners Eisai and Biogen are moving their oral beta-secretase cleaving enzyme (BACE) inhibitor E2609 into Phase III. There they join other major biopharmas…

Editas Medicine has done a deal with gene therapy small cap Adverum to introduce genome editing into diseased retina via gene therapy vectors.

With Ablynx's rheumatoid arthritis drug missing its primary endpoint, it is as unclear as ever whether AbbVie will pay $75 million to license the program.